{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:28:48Z","timestamp":1791264528704,"version":"4.1.0"},"reference-count":103,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T00:00:00Z","timestamp":1283212800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Bone is the most common site for metastasis from solid tumors, and the majority of patients will develop bone metastases during the natural course of their disease. Bisphosphonates are an effective treatment for preventing skeletal\u2010related events in patients with bone metastases and may preserve functional independence and quality of life. Although several bisphosphonates have been investigated in patients with solid tumors, only zoledronic acid (ZOL) is approved by the US Food and Drug Administration and the European Medicines Agency for preventing skeletal\u2010related events in patients across a broad range of solid tumors. In addition, bisphosphonates, notably ZOL, prevent cancer treatment\u2010induced bone loss in breast and prostate cancer patients who are receiving endocrine therapy. It also has been demonstrated that ZOL directly and indirectly inhibits cancer cell growth in vitro and growth and tumorigenesis in animal model systems. These properties may produce clinically meaningful benefits. In recent clinical studies in patients with cancer, ZOL improved overall and prolonged disease\u2010free survival. Ongoing clinical trials in patients with solid tumors will provide further insight into the potential of ZOL to prevent distant metastases and improve survival. Cancer 2011. \u00a9 2010 American Cancer Society.<\/jats:p>","DOI":"10.1002\/cncr.25529","type":"journal-article","created":{"date-parts":[[2010,8,31]],"date-time":"2010-08-31T19:17:44Z","timestamp":1283282264000},"page":"11-23","source":"Crossref","is-referenced-by-count":49,"title":["Zoledronic acid use in cancer patients"],"prefix":"10.1002","volume":"117","author":[{"given":"Robert","family":"Coleman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Hirsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,8,31]]},"reference":[{"key":"e_1_2_13_2_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.9-90004-14"},{"key":"e_1_2_13_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8 <1588::AID-CNCR9>3.0.CO;2-G"},{"key":"e_1_2_13_4_2","first-page":"205","article-title":"Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention","volume":"2","author":"Lipton A","year":"2004","journal-title":"J Support Oncol."},{"key":"e_1_2_13_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.10.002"},{"key":"e_1_2_13_6_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603659"},{"key":"e_1_2_13_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2007.07.003"},{"key":"e_1_2_13_8_2","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2007.n.016"},{"key":"e_1_2_13_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11571"},{"key":"e_1_2_13_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701"},{"key":"e_1_2_13_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20308"},{"key":"e_1_2_13_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djh141"},{"key":"e_1_2_13_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602551"},{"key":"e_1_2_13_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.03.006"},{"key":"e_1_2_13_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806285"},{"key":"e_1_2_13_16_2","unstructured":"FrassoldatiA BrufskyA BundredN et al.The effect of zoledronic acid on aromatase inhibitor\u2010associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 24\u2010month integrated follow\u2010up of the Z\u2010FAST and ZO\u2010FAST trials [poster]. Poster presented at: 33rd Congress of the European Society for Medical Oncology; September 12\u201016 2008; Stockholm Sweden. Abstract 185 PD."},{"key":"e_1_2_13_17_2","doi-asserted-by":"crossref","unstructured":"WinterMC ThorpeHC BurkinshawR BeeversSJ ColemanRE.The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response\u2014exploratory evidence for direct anti\u2010tumor activity in breast cancer [poster]. Poster presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10\u201014 2008; San Antonio Texas. Abstract 5101.","DOI":"10.1158\/0008-5472.SABCS-5101"},{"key":"e_1_2_13_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.02.004"},{"key":"e_1_2_13_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.37421"},{"key":"e_1_2_13_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc867"},{"key":"e_1_2_13_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-4096.2004.04831.x"},{"key":"e_1_2_13_22_2","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-06-0684"},{"key":"e_1_2_13_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603740"},{"key":"e_1_2_13_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11330"},{"key":"e_1_2_13_25_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1727"},{"key":"e_1_2_13_26_2","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01061"},{"key":"e_1_2_13_27_2","doi-asserted-by":"publisher","DOI":"10.1159\/000092489"},{"key":"e_1_2_13_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20602"},{"key":"e_1_2_13_29_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1545"},{"key":"e_1_2_13_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djn240"},{"key":"e_1_2_13_31_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1543"},{"key":"e_1_2_13_32_2","first-page":"1109","article-title":"Breast tumour growth inhibition in vitro through the combination of cyclophosphamide\/metotrexate\/5\u2010fluorouracil, epirubicin\/cyclophosphamide, epirubicin\/paclitaxel, and epirubicin\/docetaxel with the bisphosphonates ibandronate and zoledronic acid","volume":"12","author":"Vogt U","year":"2004","journal-title":"Oncol Rep."},{"key":"e_1_2_13_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.COC.0000074165.90133.40"},{"key":"e_1_2_13_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.cad.0000175582.01446.6f"},{"key":"e_1_2_13_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24756"},{"key":"e_1_2_13_36_2","first-page":"295","article-title":"Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer","volume":"9","author":"Corey E","year":"2003","journal-title":"Clin Cancer Res."},{"key":"e_1_2_13_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk054"},{"issue":"3","key":"e_1_2_13_38_2","first-page":"32","article-title":"Androgen deprivation enhances bone loss and prostate cancer metastases to bone: prevention by zoledronic acid","volume":"17","author":"Padalecki SS","year":"2003","journal-title":"Oncology."},{"key":"e_1_2_13_39_2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.11.2027"},{"key":"e_1_2_13_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0325"},{"key":"e_1_2_13_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa074941"},{"key":"e_1_2_13_42_2","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone\u2010stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier P","year":"2002","journal-title":"Cancer Res."},{"key":"e_1_2_13_43_2","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenetic factors in cancer patients","volume":"8","author":"Santini D","year":"2002","journal-title":"Clin Cancer Res."},{"key":"e_1_2_13_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0551"},{"key":"e_1_2_13_45_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2005.25.144"},{"key":"e_1_2_13_46_2","first-page":"327","article-title":"Bevacizumab in the treatment of metastatic breast cancer","volume":"23","author":"Traina TA","year":"2009","journal-title":"Oncology (Williston Park)."},{"key":"e_1_2_13_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700003"},{"key":"e_1_2_13_48_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.384.013k07_384_392"},{"key":"e_1_2_13_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20987"},{"key":"e_1_2_13_50_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-008-0521-6"},{"key":"e_1_2_13_51_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc865"},{"key":"e_1_2_13_52_2","unstructured":"LinA ParkJ MeliskoM et al.Zoledronic acid as adjuvant therapy for women with early stage breast cancer and occult tumor cells in bone marrow [poster]. Poster presented at: 30th Annual San Antonio Breast Cancer Symposium; December 13\u201016 2007; San Antonio Texas. Abstract 510."},{"key":"e_1_2_13_53_2","doi-asserted-by":"crossref","unstructured":"LinAY ParkJW ScottJ et al.Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [poster]. Poster presented at: 44th Annual Meeting of the American Society of Clinical Oncology; May 30\u2010June 3 2008; Chicago Illinois. Abstract 559.","DOI":"10.1200\/jco.2008.26.15_suppl.559"},{"issue":"1","key":"e_1_2_13_54_2","first-page":"S40","article-title":"Effect of zoledronate on persisting isolated tumor cells in the bone marrow of patients without recurrence of early breast cancer","volume":"106","author":"Rack BK","year":"2007","journal-title":"Breast Cancer Res Treat."},{"key":"e_1_2_13_55_2","unstructured":"SolomayerEF GebauerG HirnleP et al.Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [poster]. Poster presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10\u201014 2008; San Antonio Texas. Abstract 2048."},{"issue":"1","key":"e_1_2_13_56_2","first-page":"S38","article-title":"Effect of zoledronic acid on bone loss in women undergoing chemotherapy for breast cancer","volume":"106","author":"Aft R","year":"2007","journal-title":"Breast Cancer Res Treat."},{"key":"e_1_2_13_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23529"},{"key":"e_1_2_13_58_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.19.1458"},{"key":"e_1_2_13_59_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22991"},{"key":"e_1_2_13_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05740.x"},{"key":"e_1_2_13_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eursup.2007.03.006"},{"key":"e_1_2_13_62_2","doi-asserted-by":"publisher","DOI":"10.1385\/MO:22:2:195"},{"key":"e_1_2_13_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23783"},{"key":"e_1_2_13_64_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02698044"},{"key":"e_1_2_13_65_2","doi-asserted-by":"crossref","first-page":"257s","DOI":"10.1200\/jco.2008.26.15_suppl.5033","article-title":"A controlled prospective randomized placebo\u2010controlled trial of zoledronic acid in bony metastatic bladder cancer patients","volume":"26","author":"Zaghloul MS","year":"2008","journal-title":"J Clin Oncol."},{"key":"e_1_2_13_66_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24470"},{"key":"e_1_2_13_67_2","first-page":"3693","article-title":"Randomized controlled clinical trial of a combination of somatostatin analog and dexamethasone plus zoledronate vs. zoledronate in patients with androgen ablation\u2010refractory prostate cancer","volume":"26","author":"Mitsiades CS","year":"2006","journal-title":"Anticancer Res."},{"key":"e_1_2_13_68_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.06.091"},{"key":"e_1_2_13_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23529"},{"key":"e_1_2_13_70_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181651c0e"},{"key":"e_1_2_13_71_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-9-1035"},{"key":"e_1_2_13_72_2","doi-asserted-by":"crossref","unstructured":"ColemanRE CookRJ SaadF et al.Meta\u2010analysis of effects of zoledronic acid on survival in patients with metastatic bone disease and high bone turnover [poster]. Poser presented at: VII International Meeting on Cancer Induced Bone Disease; June 29\u2010July 2 2008; Edinburgh Scotland. Poster P81.","DOI":"10.1016\/j.ctrv.2008.03.120"},{"key":"e_1_2_13_73_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn164"},{"key":"e_1_2_13_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3744"},{"key":"e_1_2_13_75_2","doi-asserted-by":"publisher","DOI":"10.3816\/CBC.2009.n.015"},{"key":"e_1_2_13_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(06)80035-2"},{"key":"e_1_2_13_77_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23259"},{"key":"e_1_2_13_78_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7102"},{"key":"e_1_2_13_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1359-6349(07)70770-X"},{"key":"e_1_2_13_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70204-3"},{"key":"e_1_2_13_81_2","doi-asserted-by":"crossref","unstructured":"EidtmannH BundredN de BoerR et al.The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving letrozole: 36 months follow\u2010up of ZO\u2010FAST [oral presentation]. Presented orally at: 32nd Annual San Antonio Breast Cancer Symposium; December 10\u201014 2008; San Antonio Texas. Abstract 44.","DOI":"10.1158\/0008-5472.SABCS-44"},{"key":"e_1_2_13_82_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2007-0206"},{"key":"e_1_2_13_83_2","unstructured":"LlombartA FrassoldatiA PaijaO et al.Effect of zoledronic acid on aromatase inhibitor\u2010associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E\u2010ZO\u2010FAST [abstract]. Paper presented at: American Society of Clinical Oncology 2009 Breast Cancer Symposium; October 8\u201010 2009; San Francisco California. Abstract 213."},{"key":"e_1_2_13_84_2","doi-asserted-by":"crossref","unstructured":"ColemanR BundredN de BoerR et al.Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z\u2010FAST ZO\u2010FAST and E\u2010ZO\u2010FAST [poster]. Poster presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9\u201013 2009; San Antonio Texas. Abstract 4082.","DOI":"10.1158\/0008-5472.SABCS-09-4082"},{"key":"e_1_2_13_85_2","unstructured":"University of Sheffield. Chemotherapy and\/or Hormone Therapy With or Without Zoledronate in Treating Women With Stage II or Stage III Breast Cancer. ClinicalTrials.gov Identifier NCT00072020.http:\/\/clinicaltrials. gov\/ct2\/show\/NCT00072020. Accessed December 14 2009."},{"key":"e_1_2_13_86_2","doi-asserted-by":"publisher","DOI":"10.1186\/bcr1384"},{"key":"e_1_2_13_87_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.11.080"},{"key":"e_1_2_13_88_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199808063390601"},{"key":"e_1_2_13_89_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.1.10"},{"key":"e_1_2_13_90_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603661"},{"key":"e_1_2_13_91_2","unstructured":"German Breast Group. Study in Elderly Patients With Early Breast Cancer (ICE). ClinicalTrials.gov Identifier NCT00196859.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00196859?term=ICE&intr=ibandronate&rank=1. Accessed December 14 2009."},{"key":"e_1_2_13_92_2","unstructured":"German Breast Group. A Study to Compare ETC vs EC\u2010TX and Ibandronate vs Observation in Patients With Node\u2010Positive Primary Breast Cancer (GAIN). ClinicalTrials.gov Identifier NCT00196872.http:\/\/clinicaltrials.gov\/ct2\/show\/NT00196872?term=GAIN&intr=ibandronate&rank=1. Accessed December 14 2009."},{"key":"e_1_2_13_93_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.11-90001-13"},{"key":"e_1_2_13_94_2","unstructured":"Sheffield Teaching Hospitals NHS Foundation Trust. Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre\u2010Operative Chemotherapy in Breast Cancer (ANZAC). ClinicalTrials.gov Identifier NCT00525759.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00525759?term= breast+zoledronic+acid+chemotherapy. Accessed December 14 2009."},{"key":"e_1_2_13_95_2","unstructured":"German Breast Group. Postoperative Use of Zoledronic Acid in Breast Cancer Patients After Neoadjuvant Chemotherapy (NATAN). ClinicalTrials.gov Identifier NCT00512993.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00512993. Accessed December 14 2009."},{"key":"e_1_2_13_96_2","unstructured":"The SUCCESS Study Group. [News from the SUCCESS study].http:\/\/www.success\u2010studie.de\/a\/news_text.htm. Accessed December 14 2009."},{"key":"e_1_2_13_97_2","unstructured":"Southwest Oncology Group. Zoledronate Clodronate or Ibandronate in Treating Women Who Have Undergone Surgery For Stage I Stage II or Stage III Breast Cancer. ClinicalTrials.gov Identifier NCT00127205.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00127205. Accessed December 14 2009."},{"key":"e_1_2_13_98_2","unstructured":"European Association of Urology. Effectiveness of Zometa Treatment for the Prevention of Bone Metastases in High Risk Prostate Cancer Patients: A Randomised Open\u2010Label Multicentre Study of the European Association of Urology (EAU) in Cooperation with the Scandinavian Prostate Cancer Group (SPCG) and the Arbeitsgemeinschaft Urologische Onkologie (AUO). ISRCTN Register no. 66626762.http:\/\/www.controlled\u2010trials.com\/ISRCTN66626762\/zeus. Accessed December 14 2009."},{"key":"e_1_2_13_99_2","unstructured":"Trans\u2010Tasman Radiation Oncology Group. RADAR Trial\u2014Randomized Androgen Deprivation and Radiotherapy. ClinicalTrials.gov Identifier NCT00193856.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00193856. Accessed December 14 2009."},{"key":"e_1_2_13_100_2","unstructured":"Medical Research Council. Androgen Suppression Alone or Combined With Zoledronate Docetaxel Prednisolone and\/or Celecoxib in Treating Patients With Locally Advanced or Metastatic Prostate Cancer. ClinicalTrials.gov Identifier NCT00268476.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00268476?term=stamped&rank=1. Accessed December 14 2009."},{"key":"e_1_2_13_101_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2008.08034.x"},{"key":"e_1_2_13_102_2","unstructured":"Novartis. A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non\u2010Small Cell Lung Cancer. ClinicalTrials.gov Identifier NCT00172042.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00172042?term=NCT00172042&rank=1. Accessed December 14 2009."},{"key":"e_1_2_13_103_2","unstructured":"Gleneagles Hospital. Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma (dtZ). ClinicalTrials. gov Identifier NCT00263484.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00263484. Accessed December 14 2009."},{"key":"e_1_2_13_104_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70201-3"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.25529","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.25529","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:43:41Z","timestamp":1760276621000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.25529"}},"subtitle":["More than just supportive care?"],"short-title":[],"issued":{"date-parts":[[2010,8,31]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1002\/cncr.25529"],"URL":"https:\/\/doi.org\/10.1002\/cncr.25529","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8,31]]}}}